Schlieren-based Molecular Partners reported preclinical proof of concept for MP0632, a protein therapeutic designed to activate T cells only after recognising two tumour markers together. The company reported regression of established tumours expressing both mesothelin and EpCAM, with minimal effects on tumours expressing just one of the markers.
The Switch-DARPin design exposes its CD3-binding component when both targets are engaged and adds CD2 co-stimulation to strengthen the immune response. The AACR data package also reported low cytokine release during tumour-cell killing. MP0632 was selected as the company's first logic-gated T-cell engager candidate for ovarian cancer and other solid tumours carrying the two markers.
